Shabaz Sultan1, Mark A J Gorris1,2, I Jolanda M de Vries1, Niven Mehra3,4, Sandra van Wilpe5,1, Diederik M Somford6, Heidi V N Kusters-Vandevelde7, Rutger H T Koornstra8, Winald R Gerritsen5,1, Michiel Simons9, Antoine G van der Heijden10. 1. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Oncode Institute, Nijmegen, The Netherlands. 3. Department of Medical Oncology, The Radboud University Medical Center, Nijmegen, The Netherlands. niven.mehra@radboudumc.nl. 4. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. niven.mehra@radboudumc.nl. 5. Department of Medical Oncology, The Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands. 7. Department of Pathology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 8. Department of Medical Oncology, Rijnstate Hospital, Arnhem, The Netherlands. 9. Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 10. Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Whereas neoadjuvant cisplatin-based chemotherapy (NAC) followed by a radical cystectomy remains the standard treatment for patients with muscle-invasive bladder cancer (MIBC), increasing evidence suggests that checkpoint inhibitors, either alone or in combination with chemotherapy, are effective in the (neo)adjuvant setting. The major aim of this study was to improve our understanding of the immune-modulating effects of NAC in MIBC. METHODS: Tumor tissue of 81 patients was used, including 60 patients treated with NAC and 21 patients undergoing upfront cystectomy. Multiplex immunohistochemistry was performed to assess CD3+, CD3+CD8+, CD3+CD8-FoxP3-, CD3+FoxP3+, and CD20+ cells. Patients were classified into a favorable or unfavorable outcome group based on the development of a recurrence within a year. RESULTS: The density of intratumoral CD3+ T cells decreased following NAC in patients with a recurrence at one year, while it remained stable in patients without a recurrence (median fold change 0.6 [95CI 0.3; 1.0] versus 1.0 [95CI 0.6; 2.2]). This decrease was mainly attributable to a decrease in CD3+CD8-FoxP3- and CD3+FoxP3+ T cells and was not observed in patients with an early recurrence after upfront cystectomy. Additionally, in cystectomy tissue of patients treated with NAC, median CD3+ and CD3+CD8+ T cell densities were significantly lower in patients with versus patients without a recurrence (CD3: 261. cells/mm2 [95CI 22.4; 467.2]; CD8: 189.6 cells/mm2 [95CI 2.0;462.0]). CONCLUSION: T cell density decreases following NAC in MIBC patients with poor clinical outcome. Further research is needed to investigate whether this decrease in T cell density affects the efficacy of subsequent checkpoint inhibitors. PRéCIS: The major aim of this study was to improve our understanding of the immune-modulating effects of NAC in patients with MIBC. We reveal a decline in intratumoral CD3+ T cell density following NAC in patients with an early recurrence.
BACKGROUND: Whereas neoadjuvant cisplatin-based chemotherapy (NAC) followed by a radical cystectomy remains the standard treatment for patients with muscle-invasive bladder cancer (MIBC), increasing evidence suggests that checkpoint inhibitors, either alone or in combination with chemotherapy, are effective in the (neo)adjuvant setting. The major aim of this study was to improve our understanding of the immune-modulating effects of NAC in MIBC. METHODS: Tumor tissue of 81 patients was used, including 60 patients treated with NAC and 21 patients undergoing upfront cystectomy. Multiplex immunohistochemistry was performed to assess CD3+, CD3+CD8+, CD3+CD8-FoxP3-, CD3+FoxP3+, and CD20+ cells. Patients were classified into a favorable or unfavorable outcome group based on the development of a recurrence within a year. RESULTS: The density of intratumoral CD3+ T cells decreased following NAC in patients with a recurrence at one year, while it remained stable in patients without a recurrence (median fold change 0.6 [95CI 0.3; 1.0] versus 1.0 [95CI 0.6; 2.2]). This decrease was mainly attributable to a decrease in CD3+CD8-FoxP3- and CD3+FoxP3+ T cells and was not observed in patients with an early recurrence after upfront cystectomy. Additionally, in cystectomy tissue of patients treated with NAC, median CD3+ and CD3+CD8+ T cell densities were significantly lower in patients with versus patients without a recurrence (CD3: 261. cells/mm2 [95CI 22.4; 467.2]; CD8: 189.6 cells/mm2 [95CI 2.0;462.0]). CONCLUSION: T cell density decreases following NAC in MIBC patients with poor clinical outcome. Further research is needed to investigate whether this decrease in T cell density affects the efficacy of subsequent checkpoint inhibitors. PRéCIS: The major aim of this study was to improve our understanding of the immune-modulating effects of NAC in patients with MIBC. We reveal a decline in intratumoral CD3+ T cell density following NAC in patients with an early recurrence.
Authors: Joaquim Bellmunt; Maha Hussain; Jürgen E Gschwend; Peter Albers; Stephane Oudard; Daniel Castellano; Siamak Daneshmand; Hiroyuki Nishiyama; Martin Majchrowicz; Viraj Degaonkar; Yi Shi; Sanjeev Mariathasan; Petros Grivas; Alexandra Drakaki; Peter H O'Donnell; Jonathan E Rosenberg; Daniel M Geynisman; Daniel P Petrylak; Jean Hoffman-Censits; Jens Bedke; Arash Rezazadeh Kalebasty; Yousef Zakharia; Michiel S van der Heijden; Cora N Sternberg; Nicole N Davarpanah; Thomas Powles Journal: Lancet Oncol Date: 2021-03-12 Impact factor: 41.316
Authors: Ming Yin; Monika Joshi; Richard P Meijer; Michael Glantz; Sheldon Holder; Harold A Harvey; Matthew Kaag; Elisabeth E Fransen van de Putte; Simon Horenblas; Joseph J Drabick Journal: Oncologist Date: 2016-04-06
Authors: Romain Banchereau; Daniel Castellano; Thomas Powles; Mark Kockx; Alejo Rodriguez-Vida; Ignacio Duran; Simon J Crabb; Michiel S Van Der Heijden; Bernadett Szabados; Albert Font Pous; Gwenaelle Gravis; Urbano Anido Herranz; Andrew Protheroe; Alain Ravaud; Denis Maillet; Maria Jose Mendez; Cristina Suarez; Mark Linch; Aaron Prendergast; Pieter-Jan van Dam; Diana Stanoeva; Sofie Daelemans; Sanjeev Mariathasan; Joy S Tea; Kelly Mousa Journal: Nat Med Date: 2019-11-04 Impact factor: 53.440
Authors: Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning Journal: J Clin Oncol Date: 2005-07-20 Impact factor: 44.544
Authors: Andrea Necchi; Daniele Raggi; Andrea Gallina; Russell Madison; Maurizio Colecchia; Roberta Lucianò; Rodolfo Montironi; Patrizia Giannatempo; Elena Farè; Filippo Pederzoli; Marco Bandini; Marco Bianchi; Renzo Colombo; Giorgio Gandaglia; Nicola Fossati; Laura Marandino; Umberto Capitanio; Federico Dehò; Siraj M Ali; Jon H Chung; Jeffrey S Ross; Andrea Salonia; Alberto Briganti; Francesco Montorsi Journal: Eur Urol Date: 2019-11-08 Impact factor: 20.096
Authors: Tracy L Rose; Michael R Harrison; Allison M Deal; Sundhar Ramalingam; Young E Whang; Blaine Brower; Mary Dunn; Chelsea K Osterman; Hillary M Heiling; Marc A Bjurlin; Angela B Smith; Matthew E Nielsen; Hung-Jui Tan; Eric Wallen; Michael E Woods; Daniel George; Tian Zhang; Anthony Drier; William Y Kim; Matthew I Milowsky Journal: J Clin Oncol Date: 2021-08-24 Impact factor: 50.717
Authors: Jianjun Gao; Neema Navai; Omar Alhalabi; Arlene Siefker-Radtke; Matthew T Campbell; Rebecca Slack Tidwell; Charles C Guo; Ashish M Kamat; Surena F Matin; John C Araujo; Amishi Y Shah; Pavlos Msaouel; Paul Corn; Jianbo Wang; John N Papadopoulos; Shalini S Yadav; Jorge M Blando; Fei Duan; Sreyashi Basu; Wenbin Liu; Yu Shen; Yuwei Zhang; Marc Daniel Macaluso; Ying Wang; Jianfeng Chen; Jianhua Zhang; Andrew Futreal; Colin Dinney; James P Allison; Sangeeta Goswami; Padmanee Sharma Journal: Nat Med Date: 2020-10-12 Impact factor: 87.241
Authors: Nick van Dijk; Alberto Gil-Jimenez; Karina Silina; Kees Hendricksen; Laura A Smit; Jeantine M de Feijter; Maurits L van Montfoort; Charlotte van Rooijen; Dennis Peters; Annegien Broeks; Henk G van der Poel; Annemarie Bruining; Yoni Lubeck; Karolina Sikorska; Thierry N Boellaard; Pia Kvistborg; Daniel J Vis; Erik Hooijberg; Ton N Schumacher; Maries van den Broek; Lodewyk F A Wessels; Christian U Blank; Bas W van Rhijn; Michiel S van der Heijden Journal: Nat Med Date: 2020-10-12 Impact factor: 53.440
Authors: Dean F Bajorin; J Alfred Witjes; Jürgen E Gschwend; Michael Schenker; Begoña P Valderrama; Yoshihiko Tomita; Aristotelis Bamias; Thierry Lebret; Shahrokh F Shariat; Se Hoon Park; Dingwei Ye; Mads Agerbaek; Deborah Enting; Ray McDermott; Pablo Gajate; Avivit Peer; Matthew I Milowsky; Alexander Nosov; João Neif Antonio; Krzysztof Tupikowski; Laurence Toms; Bruce S Fischer; Anila Qureshi; Sandra Collette; Keziban Unsal-Kacmaz; Edward Broughton; Dimitrios Zardavas; Henry B Koon; Matthew D Galsky Journal: N Engl J Med Date: 2021-06-03 Impact factor: 91.245